ABNOM
☆ Fir-riżultati ta' Stiftung Warentest tal-2022 mill-Ġermanja, is-sodisfazzjon tal-konsumatur b'ModelDerm kien biss ftit inqas milli b'konsultazzjonijiet bit-telemediċina mħallsa.
References
Il-laser Q-switched Nd:YAG huwa magħruf li jittratta b'mod effettiv in-nevus ta 'Ota u kundizzjonijiet simili. Mexxejna studju biex naraw kemm il-laser high-fluence 1064 nm Q-switched Nd:YAG ħadem tajjeb fuq spots Mongoljani f'żoni mhux tas-soltu, mingħajr ma wassal biex il-ġilda titħaffef. Studjajna 61 pazjent b'dawn it-tikek, u eżaminajna total ta' 70 leżjoni. Nofs il-leżjonijiet ġew ittrattati bil-lejżer, filwaqt li oħrajn tħallew mhux trattati għal tqabbil. Aħna evalwajna r-riżultati bl-użu ta 'skala u apparat imsejjaħ Mexameter® biex ikejjel il-livelli ta' melanin. Il-pazjenti ġew segwiti għal medja ta' 14-il xahar fil-grupp ta' trattament u 18-il xahar fil-grupp ta' osservazzjoni. Fl-aħħar tal-istudju, sibna differenzi sinifikanti fil-punteġġi tal-iskala u l-livelli tal-melanin bejn il-gruppi ttrattati u mhux ittrattati, bil-grupp ittrattat bil-laser juri riżultati aħjar. Il-laser high-fluence Q-switched Nd:YAG , mingħajr ma kkawża tħaffif tal-ġilda, wera li huwa effettiv u sikur għat-trattament ta 'dawn it-tikek Mongoljani mhux tas-soltu.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Studjajna l-effettività u s-sigurtà tal-użu ta’ trattament speċifiku bil-laser għal ABNOM , u ħares lejn liema fatturi jistgħu jaffettwaw kemm jaħdem tajjeb. Ħarsa lejn 110 pazjent li kellhom ABNOM u ħadu bejn żewġ u disa’ trattamenti bil-laser. Sibna li t-trattament ħadem aħjar iktar ma sar, iżda mhux daqshekk tajjeb f’pazjenti anzjani. Ħadem aħjar ukoll f'pazjenti b'ġilda eħfef (tip III) u żoni affettwati iżgħar (inqas minn 10 cm2) . Li jkollok melasma flimkien ma ' ABNOM għamel it-trattament inqas effettiv. Il-kulur jew in-numru ta 'żoni affettwati ma dehrux li jagħmlu differenza. Madwar 10% tal-pazjenti kisbu tikek skuri wara t-trattament. It-trattament multiplu bikri ta riżultati tajbin. Pazjenti anzjani b'ġilda skura u tikek skuri huma aktar probabbli li jkollhom tikek skuri wara t-trattament. Għal pazjenti b' ABNOM u melasma, huwa aħjar li tuża laser b'enerġija aktar baxxa biex tevita li tagħmel il-melasma agħar.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Trattament
L-aġenti li jbajdu rari jgħinu. B'differenza mill-melasma, ABNOM jista 'jitjieb bit-trattament bil-laser u jitħalla jitneħħa mingħajr rikorrenza. It-trattament bil-lejżer jista 'jsir 10 sa 20 darba biex jittratta ABNOM.
#QS1064 laser